{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:08:30Z","timestamp":1790251710021,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03063-5","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:22:01Z","timestamp":1784532121000},"page":"2202-2215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia"],"prefix":"10.1038","volume":"40","author":[{"given":"Zhixiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongbin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuquan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6243-921X","authenticated-orcid":false,"given":"Yingying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinggang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7428-8682","authenticated-orcid":false,"given":"Shaoyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"3063_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","volume":"17","author":"MS Tallman","year":"2019","unstructured":"Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2019;17:721\u201349.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"3063_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","volume":"19","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Cancer Netw JNCCN. 2021;19:16\u201327.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"3063_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"3063_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"3063_CR5","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022;40:4048\u201359.","journal-title":"J Clin Oncol"},{"key":"3063_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106:894\u20138.","journal-title":"Haematologica"},{"key":"3063_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"3063_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanm\u00e4ki","year":"2020","unstructured":"Kuusanm\u00e4ki H, Lepp\u00e4 AM, P\u00f6l\u00f6nen P, Kontro M, Dufva O, Deb D, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105:708\u201320.","journal-title":"Haematologica"},{"key":"3063_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"3063_CR10","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2019004326","volume":"136","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, et al. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136:2918\u201326.","journal-title":"Blood"},{"key":"3063_CR11","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/cncr.33689","volume":"127","author":"K Kim","year":"2021","unstructured":"Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127:3772\u201381.","journal-title":"Cancer"},{"key":"3063_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","volume":"145","author":"J Belmar","year":"2015","unstructured":"Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Therapeut. 2015;145:76\u201384.","journal-title":"Pharmacol Therapeut"},{"key":"3063_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41419-022-05500-6","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Gao F, Li X, Gan Y, Han S, Yu X, et al. Stabilization of MCL-1 by E3 ligase TRAF4 confers radioresistance. Cell Death Dis. 2022;13:1053.","journal-title":"Cell Death Dis"},{"key":"3063_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ijbiomac.2021.07.166","volume":"187","author":"P Mittal","year":"2021","unstructured":"Mittal P, Singh S, Sinha R, Shrivastava A, Singh A, Singh IK. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy. Int J Biol Macromol. 2021;187:999\u20131018.","journal-title":"Int J Biol Macromol"},{"key":"3063_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3324\/haematol.2020.260331","volume":"107","author":"BZ Carter","year":"2022","unstructured":"Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022;107:58\u201376.","journal-title":"Haematologica"},{"key":"3063_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.12","volume":"2","author":"DA Luedtke","year":"2017","unstructured":"Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transd Target Ther. 2017;2:17012.","journal-title":"Signal Transd Target Ther"},{"key":"3063_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Mol Cell. 2005;17:393\u2013403.","journal-title":"Mol Cell"},{"key":"3063_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","volume":"118","author":"AA Morales","year":"2011","unstructured":"Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011;118:1329\u201339.","journal-title":"Blood"},{"key":"3063_CR19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov. 2018;8:1566\u201381.","journal-title":"Cancer Discov"},{"key":"3063_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","volume":"3","author":"J Yuda","year":"2023","unstructured":"Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med. 2023;3:154.","journal-title":"Commun Med"},{"key":"3063_CR21","unstructured":"U.S. National Library of Medicine, AMG-176: A Study of Venetoclax and AMG 176 in Patients With Relapsed\/ Refractory Hematologic Malignancies. https:\/\/clinicaltrials.gov\/study\/NCT03797261."},{"key":"3063_CR22","unstructured":"U.S. National Library of Medicine, AZD5991: Study of AZD5991 alone or in combination with venetoclax in relapsed or refractory haematologic malignancies. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03218683."},{"key":"3063_CR23","unstructured":"U.S. National Library of Medicine, AMG-397: Safety, tolerability, pharmacokinetics and efficacy of AMG 397 in subjects with selected relapsed or refractory hematological malignancies. https:\/\/clinicaltrials.gov\/show\/NCT03465540."},{"key":"3063_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1073\/pnas.1525387114","volume":"114","author":"N Gupta","year":"2017","unstructured":"Gupta N, Badeaux M, Liu Y, Naxerova K, Sgroi D, Munn LL, et al. Stress granule-associated protein G3BP2 regulates breast tumor initiation. Proc Natl Acad Sci USA. 2017;114:1033\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3063_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455\u201361.","journal-title":"J Comput Chem"},{"key":"3063_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2026.110931","volume":"292","author":"H Liu","year":"2026","unstructured":"Liu H, Jiang L, Bu Q, Sun M, Zhao Y, He Y, et al. Ciprofloxacin exposure impairs neurogenesis and E\/I balance in human cortical organoids. Neuropharmacology. 2026;292:110931.","journal-title":"Neuropharmacology"},{"key":"3063_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-S4-S2","volume":"13","author":"E Bramucci","year":"2012","unstructured":"Bramucci E, Paiardini A, Bossa F, Pascarella S. PyMod: sequence similarity searches, multiple sequence-structure alignments, and homology modeling within PyMOL. BMC Bioinforma. 2012;13:S2.","journal-title":"BMC Bioinforma"},{"key":"3063_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"3063_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.19","volume":"5","author":"E Saland","year":"2015","unstructured":"Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, et al. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer J. 2015;5:e297.","journal-title":"Blood Cancer J"},{"key":"3063_CR30","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/10428194.2021.1910684","volume":"62","author":"KL Walker","year":"2021","unstructured":"Walker KL, Rinella SP, Hess NJ, Turicek DP, Kabakov SA, Zhu F, et al. CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1\/2 and BCL2 inhibition through CNS infiltration. Leuk lymphoma. 2021;62:1167\u201377.","journal-title":"Leuk lymphoma"},{"key":"3063_CR31","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/s41375-023-01951-8","volume":"37","author":"K Weidenauer","year":"2023","unstructured":"Weidenauer K, Schmidt C, Rohde C, Pauli C, Blank MF, Heid D, et al. The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax\/azacitidine in acute myeloid leukemia. Leukemia. 2023;37:1611\u201325.","journal-title":"Leukemia"},{"key":"3063_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"3063_CR33","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3324\/haematol.2018.205534","volume":"105","author":"L Han","year":"2020","unstructured":"Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020;105:697\u2013707.","journal-title":"Haematologica"},{"key":"3063_CR34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41388-021-02073-0","volume":"41","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Wu J, Deng R, Lin C, Huang Y, Yang X, et al. G3BP2 regulated by the lncRNA LINC01554 facilitates esophageal squamous cell carcinoma metastasis through stabilizing HDGF transcript. Oncogene. 2022;41:515\u201326.","journal-title":"Oncogene"},{"key":"3063_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/1878-0261.12915","volume":"19","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yue C, Krichevsky AM, Garkavtsev I. Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD-L1. Mol Oncol. 2021;19:558\u201371.","journal-title":"Mol Oncol"},{"key":"3063_CR36","doi-asserted-by":"publisher","first-page":"D165","DOI":"10.1093\/nar\/gkab1113","volume":"50","author":"JA Castro-Mondragon","year":"2022","unstructured":"Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, Lemma RB, Turchi L, Blanc-Mathieu R, et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2022;50:D165\u2013d173.","journal-title":"Nucleic Acids Res"},{"key":"3063_CR37","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/1541-7786.MCR-17-0471","volume":"16","author":"KI Takayama","year":"2018","unstructured":"Takayama KI, Suzuki T, Fujimura T, Takahashi S, Inoue S. Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer. Mol Cancer Res. 2018;16:846\u201356.","journal-title":"Mol Cancer Res"},{"key":"3063_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1074\/mcp.RA118.001181","volume":"18","author":"JM Noto","year":"2019","unstructured":"Noto JM, Rose KL, Hachey AJ, Delgado AG, Romero-Gallo J, Wroblewski LE, et al. Carcinogenic Helicobacter pylori Strains Selectively Dysregulate the In Vivo Gastric Proteome, Which May Be Associated with Stomach Cancer Progression. Mol Cell Proteom. 2019;18:352\u201371.","journal-title":"Mol Cell Proteom"},{"key":"3063_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13018-022-03181-7","volume":"17","author":"O Shuang","year":"2022","unstructured":"Shuang O, Zhou J, Cai Z, Liao L, Wang Y, Wang W, et al. EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p\/G3BP2 axis as a ceRNA. J Orthop Surg Res. 2022;17:332.","journal-title":"J Orthop Surg Res"},{"key":"3063_CR40","doi-asserted-by":"publisher","first-page":"e20220962","DOI":"10.1084\/jem.20220962","volume":"220","author":"T Yokomizo-Nakano","year":"2023","unstructured":"Yokomizo-Nakano T, Hamashima A, Kubota S, Bai J, Sorin S, Sun Y, et al. Exposure to microbial products followed by loss of Tet2 promotes myelodysplastic syndrome via remodeling HSCs. J Exp Med. 2023;220:e20220962.","journal-title":"J Exp Med"},{"key":"3063_CR41","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nsmb.3462","volume":"24","author":"RR Edupuganti","year":"2017","unstructured":"Edupuganti RR, Geiger S, Lindeboom RGH, Shi H, Hsu PJ, Lu Z, et al. N(6)-methyladenosine (m(6)A) recruits and repels proteins to regulate mRNA homeostasis. Nat Struct Mol Biol. 2017;24:870\u20138.","journal-title":"Nat Struct Mol Biol"},{"key":"3063_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","volume":"125","author":"R Scheicher","year":"2015","unstructured":"Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015;125:90\u2013101.","journal-title":"Blood"},{"key":"3063_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.exphem.2013.10.004","volume":"42","author":"M Wurm","year":"2014","unstructured":"Wurm M, Kowalski J, Heckl D, Zhang XB, Nelson V, Beard BC, et al. Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation. Exp Hematol. 2014;42:114\u201325.e114.","journal-title":"Exp Hematol"},{"key":"3063_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2020.1800979","volume":"9","author":"CS Hong","year":"2020","unstructured":"Hong CS, Jeong E, Boyiadzis M, Whiteside TL. Increased small extracellular vesicle secretion after chemotherapy via upregulation of cholesterol metabolism in acute myeloid leukaemia. J Extracell Ves. 2020;9:1800979.","journal-title":"J Extracell Ves"},{"key":"3063_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27:405\u201319.","journal-title":"Cell Death Differ"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03063-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:27Z","timestamp":1790250207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03063-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03063-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the Fujian Medical University Ethics Committee (2022KY195) and complied with the Declaration of Helsinki and Good Clinical Practice guidelines. Patients provided informed consent for the research use of their information. Animal experiments were approved by the university\u2019s Laboratory Animal Center (IACUC FJMU2023-Y-0933).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}